Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

Core Insights - Kamada Ltd. has initiated a post-marketing clinical trial for CYTOGAM to evaluate its effectiveness in preventing late Cytomegalovirus (CMV) infection in high-risk kidney transplant recipients [1][2][3] - The SHIELD study aims to assess the benefits of administering CYTOGAM after the conclusion of antiviral prophylaxis in patients at high risk for late CMV infection [2][3] - CMV disease poses significant risks to transplant recipients, particularly those who are CMV seronegative with a CMV seropositive donor, highlighting the need for innovative prophylactic approaches [3][5] Company Overview - Kamada Ltd. is a global biopharmaceutical company specializing in rare and serious conditions, with a focus on specialty plasma-derived therapies [1][10] - The company has a portfolio of six FDA-approved specialty plasma-derived products, including CYTOGAM, and is expanding its plasma collection operations to support revenue growth [10] - Kamada's strategy includes organic growth, business development opportunities, and advancing research and development for additional product candidates [10] Clinical Study Details - The SHIELD study is a prospective, randomized, controlled multicenter trial led by experts in CMV and organ transplantation [2][4] - The study will specifically target kidney transplant recipients who are at the highest risk of developing late-onset CMV infection [3][5] - The trial is supported by Kamada, emphasizing the company's commitment to improving transplant patient outcomes [5]